Povidone-iodine

CORRECTION: Lundquist Investigator Dr. Loren Miller Is the Lead Author of the “Universal Decolonization” Study Published in the New England Journal of Medicine

Retrieved on: 
Wednesday, October 11, 2023
Chlorhexidine, Infection, Methicillin-resistant Staphylococcus aureus, Nursing, Doctor of Philosophy, The New England Journal of Medicine, Prevalence, Epidemiology, UCI, Hospital, MPH, University of California, Irvine, University, CDC, Agency for Healthcare Research and Quality, University of California, Irvine School of Medicine, Health, Harbor–UCLA Medical Center, AHRQ, MHSA, Nursing home, Fungal infection, Long-term care, MRSA, Povidone-iodine, Houston, Clinical trial, Nose, Institute of Health and Biomedical Innovation, Korea Disease Control and Prevention Agency, Skin, UCI School of Biological Sciences, Urinary tract infection, Enterococcus-1 RNA motif, Bed, Research, NIH, Pharmaceutical industry, MD, Medicine

The findings were published on October 10, 2023, in the New England Journal of Medicine.

Key Points: 
  • The findings were published on October 10, 2023, in the New England Journal of Medicine.
  • “The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.
  • Dr. Miller is the Chief of Infectious Diseases at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center in Torrance, California.
  • “Nursing Home Decolonization for Infection and Hospitalization Prevention” published in the New England Journal of Medicine on October 10, 2023: https://www.nejm.org/doi/full/10.1056/NEJMoa2215254?query=featured_home

Lundquist Investigator Dr. Loren Miller Is the Lead Author of the “Universal Decolonization” Study Published in the New English Journal of Medicine

Retrieved on: 
Tuesday, October 10, 2023
Chlorhexidine, Infection, Methicillin-resistant Staphylococcus aureus, Nursing, Doctor of Philosophy, The New England Journal of Medicine, Prevalence, Epidemiology, UCI, Hospital, MPH, University of California, Irvine, CDC, University, Agency for Healthcare Research and Quality, University of California, Irvine School of Medicine, Health, Harbor–UCLA Medical Center, AHRQ, MHSA, Fungal infection, Long-term care, MRSA, Povidone-iodine, Houston, Clinical trial, Nose, Institute of Health and Biomedical Innovation, Korea Disease Control and Prevention Agency, Skin, UCI School of Biological Sciences, Urinary tract infection, Enterococcus-1 RNA motif, Bed, Research, NIH, Pharmaceutical industry, MD, Medicine

“The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.

Key Points: 
  • “The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.
  • Dr. Miller is the Chief of Infectious Diseases at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center in Torrance, California.
  • Each year, 3 million healthcare-associated infections (HAIs) such as methicillin-resistant Staphylococcus aureus (MRSA), bloodstream and urinary tract infections occur in U.S. nursing homes.
  • The findings add to a growing body of Dr. Miller’s research that has been funded by NIH, AHRQ, and other federal sources.

Large Clinical Trial by the Centers for Disease Control and Prevention, Harvard Pilgrim Health Care Institute, HCA Healthcare and UCI Health Identifies Best Strategy to Prevent Life-Threatening Health Care-Associated ICU Infections

Retrieved on: 
Tuesday, October 10, 2023
Research, Hospitals, Clinical Trials, Health Insurance, Other Health, Managed Care, Health, Pharmaceutical, Science, Chlorhexidine, JAMA, Multimedia, Hospital, Harvard Medical School, Bloodstream infections, Health care, Division, Mupirocin, Suggestion, Bacteria, University of California, Irvine Medical Center, Master of Science, Risk, Intensive care unit, CDC, Antimalarial medication, University, Infection, American Medical Association, CHG, MRSA, Journal, Povidone-iodine, University of California, Irvine School of Medicine, Staphylococcus aureus, REDUCE, Nose, ICU, Additive effect, HCA Healthcare, Korea Disease Control and Prevention Agency, Skin, ABATE, Patient, Harvard Pilgrim Health Care, Pharmaceutical industry, Nursing, MD, Medicine

This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.

Key Points: 
  • This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.
  • The Mupirocin-Iodophor Swap Out Trial directly compared nasal mupirocin to nasal iodophor in the context of chlorhexidine bathing.
  • “This study further supports CDC guidance on using a strategy that combines nasal decolonization plus CHG bathing in ICU patients.
  • The results resolved the question about whether nasal treatment is necessary in addition to chlorhexidine bathing to prevent these ICU infections.

Avrio Health L.P. Announces Publication of In Vitro Test Results Assessing Betadine® Formulations Against Four Coronaviruses

Retrieved on: 
Thursday, October 14, 2021
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Viral load, ASTM, Severe acute respiratory syndrome coronavirus 2, Different, Health, Method, Doctor of Philosophy, Coronaviridae, Knowledge, Master of Science, Bachelor of Pharmacy, Sore throat, Public health, Alphacoronavirus, Science, Betacoronavirus, Infection, OC43, Purdue Pharma, CEO, Povidone-iodine, Safety, MD, NL63, Research, Shet, Virus, Quality of life, Pharmaceutical industry, Medical device

Avrio Health L.P. today announced the publication of results from two in vitro laboratory studies assessing Betadine antiseptic products (active ingredient: povidone-iodine or PVP-I) against four coronaviruses used as a surrogate for SARS-CoV-2.

Key Points: 
  • Avrio Health L.P. today announced the publication of results from two in vitro laboratory studies assessing Betadine antiseptic products (active ingredient: povidone-iodine or PVP-I) against four coronaviruses used as a surrogate for SARS-CoV-2.
  • The studies, published in Infectious Diseases and Therapy , found that Betadine Topical Solution, Betadine Surgical Scrub, and Betadine Gargle demonstrated virucidal activity against the coronaviruses studied.
  • Avrio Health is committed to scientific exploration to help inform health care provider response to public health needs.
  • Betadine Topical Solution (containing 5.0% and 10.0% PVP-I), Betadine Surgical Scrub (containing 7.5% PVP-I), and Betadine Gargle (containing 0.5% PVP-I) were compared to placebo in two separate in vitro studies and showed virucidal activity against four coronaviruses.

Association of American Physicians and Surgeons (AAPS) States that Betadine Must Be Used Properly in Attempts to Prevent or Treat COVID-19

Retrieved on: 
Wednesday, October 13, 2021
Viral load, MedPage Today, Physician, Povidone-iodine, Skin, Adult, Association, Randomized controlled trial, Hospital, AAPS, Severe acute respiratory syndrome coronavirus 2, GLOBE, Fox News, COVID-19, Association of American Physicians and Surgeons, Pharmaceutical industry

The Association of American Physicians and Surgeons (AAPS) has released a statement concerning the potential benefit and safe usage of this modality.

Key Points: 
  • The Association of American Physicians and Surgeons (AAPS) has released a statement concerning the potential benefit and safe usage of this modality.
  • The AAPS statement notes that seven studies have shown efficacy in early treatment or pre-exposure prophylaxis.
  • used Betadine as acute therapy for incipient COVID-19 in a randomized controlled trial that showed significantly lower death and hospitalization rate.
  • The Association of American Physicians and Surgeons (AAPS) is a national organization representing physicians in all specialties since 1943.

Research Led by FDB Pharmacists and Health System Clinicians Further Shatters Age-Old Iodine Allergy Myth

Retrieved on: 
Wednesday, September 15, 2021
Precision medicine, Patient safety, Anaphylaxis, Food, Prescription, SAN, American Academy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDB, FDA, Steroid, Decision-making, Pharmacist, Shellfish, Seafood, Pharmacy, Mayo Clinic, Doctor of Pharmacy, MHK, Patient, Degenerative disease, Allergy, Thyroid, Society, MCG, Pharmacy management system, BCPS, YouTube, LinkedIn, Trauma, Neoplasm, Safety, Dehydration, Physician, Iodine, Solution, MD, Hearst, American Journal of Health-System Pharmacy, Asthma, Amiodarone, First Databank, Twitter, Blood, American Journal, American Academy of Allergy, Asthma, and Immunology, Radiology, Povidone-iodine, Hospital, Rash, Face, Agent handling, Research, Cancer, Tongue, American College, Sudarshan K. Aggarwal, Pharmaceutical industry, Medical imaging

The findings were recently published in the American Journal of Health-System Pharmacy , a peer-reviewed journal of the American Society of Health-System Pharmacists.

Key Points: 
  • The findings were recently published in the American Journal of Health-System Pharmacy , a peer-reviewed journal of the American Society of Health-System Pharmacists.
  • Sixty-six percent to 89% of physicians routinely ask patients prior to an imaging test if they have an iodine allergy or an allergy to shellfish or other seafood that may contain iodine.
  • FDB (First Databank) is the leading provider of drug and medical device knowledge that helps healthcare professionals make precise decisions.
  • The Hearst Health network includes FDB (First Databank), Zynx Health , MCG , Homecare Homebase and MHK (formerly MedHOK).

Purdue Pharma’s Avrio Health Launches Betadine® Antiseptic Oral Rinse for Professional Use

Retrieved on: 
Monday, February 8, 2021
Medical Supplies, Health, Surgery, Other Health, Dental, Pharmaceutical, Health, Chemistry, Physical sciences, RTT, Dosage forms, Antiseptics, Disinfectants, Polyvinylpyrrolidone, Mouthwash, Topical medication, Povidone-iodine, Iodine, Betadine, Avrio Health L.P., Purdue Pharma L.P.

Avrio Health L.P. (Avrio), a subsidiary of Purdue Pharma L.P. (Purdue), today announced the launch of new Betadine Antiseptic Oral Rinse (active ingredient 0.5% povidone-iodine, or PVP-I), an oral antiseptic pre-procedural rinse.

Key Points: 
  • Avrio Health L.P. (Avrio), a subsidiary of Purdue Pharma L.P. (Purdue), today announced the launch of new Betadine Antiseptic Oral Rinse (active ingredient 0.5% povidone-iodine, or PVP-I), an oral antiseptic pre-procedural rinse.
  • Betadine antiseptic products have been used in the hospital and outpatient settings for their antiseptic (antimicrobial) properties for more than 50 years.
  • Betadine Antiseptic Oral Rinse should be administered by professionals and used orally (do not swallow) in preparation of the oral mucosa prior to injection, dental surgery, or tooth extraction.
  • Betadine Topical Antiseptic products currently available in the U.S. are for external use only and should not be gargled or swallowed.

Global Skin Antiseptic Products Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, December 18, 2020
Health, Pharmaceutical, Antiseptics, Disinfectants, Antimicrobials, Biocides, Chemistry, Chlorhexidine, Alcohols, Iodine, Povidone-iodine

The alcohols segment led the market, owing to an increased usage of formulation for pre-injection and pre-operative skin preparation.

Key Points: 
  • The alcohols segment led the market, owing to an increased usage of formulation for pre-injection and pre-operative skin preparation.
  • Furthermore, the increasing demand for alcohol base to be used in combination with other formulations, such as iodine and chlorhexidine, is fueling the segment growth.
  • Furthermore, it comprises antiseptic agents, such as isopropyl or ethyl, which are effective against different microbes.
  • In this region the United States has the maximum share due to supportive healthcare policies, high number of patients, and a developed healthcare market.

Purdue’s Avrio Health L.P. Reports Preliminary In Vitro Test Results on Study Assessing Betadine Gargle Against COVID-19

Retrieved on: 
Thursday, August 13, 2020
Health, Infectious diseases, General Health, Clinical trials, Research, Science, Pharmaceutical, Sarbecovirus, Health, Microbiology, Animal diseases, Antiseptics, Disinfectants, Iodine, Povidone-iodine, RTT, Polyvinylpyrrolidone, Severe acute respiratory syndrome, Coronavirus

Avrio Health L.P., a subsidiary of Purdue Pharma L.P. (Purdue), is reporting encouraging preliminary results of an in vitro (laboratory) study assessing Betadine Antiseptic Sore Throat Gargle (active ingredient, povidone-iodine or PVP-I) against the virus causing COVID-19.

Key Points: 
  • Avrio Health L.P., a subsidiary of Purdue Pharma L.P. (Purdue), is reporting encouraging preliminary results of an in vitro (laboratory) study assessing Betadine Antiseptic Sore Throat Gargle (active ingredient, povidone-iodine or PVP-I) against the virus causing COVID-19.
  • Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.
  • Betadine Gargle containing 0.5% PVP-I demonstrated virucidal activity against SARS-CoV-2 and four surrogate coronaviruses in three separate in vitro studies.
  • An in vitro study conducted by Utah State University, Institute for Antiviral Research, assessed virucidal activity of Betadine Gargle against SARS-CoV-2.

Purdue Pharma’s Avrio Health Expands Betadine® Portfolio With New Over-The-Counter Antiseptic Sore Throat Gargle

Retrieved on: 
Tuesday, August 11, 2020
General Health, Pharmaceutical, Health, Chemistry, Physical sciences, Chemical substances, RTT, Antiseptics, Disinfectants, Povidone-iodine, Polyvinylpyrrolidone, Iodine, PvP

Avrio Health L.P. (Avrio), a subsidiary of Purdue Pharma L.P. (Purdue), today announced the launch of new Betadine Antiseptic Sore Throat Gargle (active ingredient povidone-iodine, or PVP-I), an oral antiseptic with use for the temporary relief of occasional sore throat.

Key Points: 
  • Avrio Health L.P. (Avrio), a subsidiary of Purdue Pharma L.P. (Purdue), today announced the launch of new Betadine Antiseptic Sore Throat Gargle (active ingredient povidone-iodine, or PVP-I), an oral antiseptic with use for the temporary relief of occasional sore throat.
  • Betadine Antiseptic Sore Throat Gargle should be used orally (do not swallow) for the temporary relief of occasional sore throat.
  • Betadine Antiseptic Sore Throat Gargle can be used by adults and children 12 years of age and older.
  • Betadine Sore Throat Gargle (0.5% povidone-iodine antiseptic gargle), which should not be ingested, relieves sore throat.